Discover why Genmab A/S stands out as a high-margin biotech with strong partnerships, robust growth prospects, and ...

Company Announcement COPENHAGEN, Denmark; June 23, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 ...

In trading on Wednesday, shares of Genmab A/S (Symbol: GMAB) crossed above their 200 day moving average of $21.99, changing hands as high as $22.15 per share. Genmab A/S shares are currently ...

Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under ...

Transactions in Connection with Share Buy-back Program. Company Announcement COPENHAGEN, Denmark; June 16, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a ...

On Tuesday, June 3, Leerink Partners analysts increased the price target for Genmab A/S (NASDAQ:GMAB) from $29 to $32 and kept an “Outperform” rating. The decision came after Genmab A/S ...

Genmab A/S (NASDAQ:GMAB) is a global biotech company focused on developing innovative antibody therapeutics to improve patient lives. With over 25 years of expertise, GMAB’s team has created ...

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference. Media ReleaseCOPENHAGEN, Denmark; May 27, 2025Genmab A/S (Nasdaq: GMAB) announced today that its ...

Quite a few of them also piled into the American Depositary Receipts (ADRs) of Danish biotech Genmab (GMAB-1.85%), on the back of encouraging news from the laboratory.

Read about Genmab AS ADR (GMAB:XNAS) stock and today's latest news and financial updates. GMAB - Genmab AS ADR News | Morningstar Morningstar brands and products ...